- Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety
- The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media
- The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal
- Delic recently received Health Canada authorization to obtain 60 grams of psilocybin mushrooms for its purposes and to conduct research using other psychedelics, such as MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B.
On April 19, 1943, a Swiss chemical researcher experienced what has come to be known as “the world’s first intentional acid trip” as he experimented with the hallucinogenic effects of lysergic acid diethylamide (“LSD“) while riding his bicycle home from work. The day subsequently became celebrated as “Bicycle Day” by the drug’s users (https://ibn.fm/WN2av).
Some 50 years after LSD and other psychedelic drugs reached their peak use in the United States, psychedelics are enjoying a new resurgence in popularity and possible legal authorization as medical researchers examine their potential to treat difficult mental disorders — particularly where psilocybin, the naturally hallucinogenic prodrug compound in “magic mushrooms,” is concerned (https://ibn.fm/mvupb).
Psychedelic wellness company Delic Holdings (CSE: DELC) (OTCQB: DELCF) is a leader in new medicines and treatments for a modern world, making the health benefits more accessible and affordable to patients, and reframing the conversation around psychedelics.
Coinciding with Bicycle Day, the company issued an update April 19 on Delic Co-founder and CEO Matt Stang’s appearances at the April 20 Sequire Cannabis and Psychedelic Conference and the April 22-24 Scottsdale Capital Event, where Stang was scheduled to meet with investors about the company’s strategic outlook for the remainder of the year and network with other industry insiders participating in the cannabis and psychedelic space (https://ibn.fm/EBwxG).
The company sponsors outreach to industry companies and consumers through its annual Meet Delic psychedelic conference, which debuted last year as “the world’s largest psychedelic wellness event” with over 2,500 attendees and 16 hours of speakers and panel sessions in Las Vegas, as well as themed music and entertainment (https://ibn.fm/13BYm). This year’s event is scheduled for early November, with tickets already on sale (https://ibn.fm/by3IK).
The scientific backbone of the company’s ecosystem is its Delic Labs research facility, which is federally authorized to work with psilocybin and cannabis to improve extraction, analytical testing and chemical processes while developing product lines and new intellectual property (“IP”).
Delic Labs recently received a Health Canada 56 Research Exemption that allows its scientists to do research with a number of compounds outside of psychedelic mushrooms, including MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B. Health Canada also authorized Delic Labs to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., and the lab has applied for a Dealer’s License that would let it commercialize its psilocybin research and associated IP for medical and research purposes.
The company also operates the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC“), which has overseen 70,000 mental health treatments to date. Delic plans to open more state-of-the-art clinics by mid-2023 as part of its growing profile.
“At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” Delic Co-founder and CEO Matt Stang stated in January (https://ibn.fm/XTey8). “There are 51.5 million Americans who have experienced a mental health condition and the ongoing pandemic has only exacerbated the crisis. We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects. … Delic is well-positioned for growth and profitability in 2022 and beyond.”
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.